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G. A. O’Toolea
Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USAa; Dartmouth-Hitchcock Medical Center, Section of Pulmonary and Critical Care Medicine,
Lebanon, New Hampshire, USAb; Josephine Bay Paul Center for Comparative Molecular Biology and Evolution, Marine Biological Laboratory, Woods Hole, Massachusetts,
USAc; The Forsyth Institute, Department of Molecular Genetics, Cambridge, Massachusetts, USAd; and Department of Oral Medicine, Infection and Immunity, Harvard
School of Dental Medicine, Boston, Massachusetts, USAe
Diverse microbial communities chronically colonize the lungs of cystic fibrosis patients. Pyrosequencing of amplicons for hyper-
variable regions in the 16S rRNA gene generated taxonomic profiles of bacterial communities for sputum genomic DNA samples
from 22 patients during a state of clinical stability (outpatients) and 13 patients during acute exacerbation (inpatients). We em-
ployed quantitative PCR (qPCR) to confirm the detection of Pseudomonas aeruginosa and Streptococcus by the pyrosequencing
data and human oral microbe identification microarray (HOMIM) analysis to determine the species of the streptococci identi-
fied by pyrosequencing. We show that outpatient sputum samples have significantly higher bacterial diversity than inpatients,
but maintenance treatment with tobramycin did not impact overall diversity. Contrary to the current dogma in the field that
Pseudomonas aeruginosa is the dominant organism in the majority of cystic fibrosis patients, Pseudomonas constituted the pre-
dominant genera in only half the patient samples analyzed and reported here. The increased fractional representation of Strepto-
coccus in the outpatient cohort relative to the inpatient cohort was the strongest predictor of clinically stable lung disease. The
most prevalent streptococci included species typically associated with the oral cavity (Streptococcus salivarius and Streptococcus
parasanguis) and the Streptococcus milleri group species. These species of Streptococcus may play an important role in increasing
the diversity of the cystic fibrosis lung environment and promoting patient stability.
Progressive decline in lung function is the primary cause ofmorbidity and mortality in cystic fibrosis (CF) patients (5).
Mutations in the cystic fibrosis transmembrane conductance reg-
ulator protein promote dehydration of the airway surface liquid of
the lung epithelium, which leads to defective mucociliary clear-
ance and increased bacterial colonization of CF patient lungs (10).
The inflammatory response to bacterial colonization causes irre-
versible lung tissue damage that progressively decreases lung func-
tion (2, 15).
Historically, CF bacterial infections were attributed to very few
species, predominately Pseudomonas aeruginosa in adults (9).
However, studies over the past decade demonstrate that the CF
lung environment can host a highly diverse polymicrobial com-
munity (22–24). The role of diverse community structure and
interspecies interactions in patient health remains poorly under-
stood. Previous reports show that increased age in CF patients
correlates with decreased lung diversity and decreased lung func-
tion (measured as forced expiratory volume in 1 s [FEV1]) (4).
Further, community composition or gene expression, rather than
total bacterial load, may dictate patient disease state (30), al-
though all of these factors likely can contribute to patient health
and disease.
While Pseudomonas remains a significant pathogen in CF, nu-
merous other aerobic and anaerobic organisms contribute to the
community complexity of the CF lung, including members of the
following genera: Rothia, Prevotella, Stenotrophomonas, Strepto-
coccus, and others (11, 31). Recent reports describe the prevalence
of viridans streptococci in the analysis of patient sputum, includ-
ing the salivarius, milleri (or anginosus), and mitis streptococcus
groups (17). The Streptococcus milleri group (SMG), which in-
cludes S. anginosus, S. constellatus, and S. intermedius, may play a
significant role in the pathogenesis of the CF lung (18, 28) by
influencing microbial community structures during periods of
clinical stability or by causing acute exacerbation in diseased pa-
tients (27).
Here, we report that increased bacterial community diversity
in CF patient sputum and increased relative abundance of the
genus Streptococcus positively correlated with patient stability.
The predominant streptococci in these patient samples included
S. salivarius, S. parasanguis, and SMG species. A complete under-
standing of the polymicrobial communities of CF patients, as well
as characterizing community features that correlate with exacer-
bation, can guide innovations to current treatment methods in
order to personalize and improve patient care.
MATERIALS AND METHODS
Patient cohort and sputum collection. The study enrollment, assessment
of inpatients versus outpatients, and a description of the clinical charac-
teristics of this patient cohort were detailed by Gifford et al. (8). Sponta-
neously expectorated sputum samples were collected during routine visits
for outpatient samples. Spontaneously expectorated inpatient sputum
samples were collected within 24 h of hospital admittance, with the excep-
tion of one sample collected within the first 72 h. For inpatients, intrave-
nous antibiotic exposure length prior to sputum expectoration was lim-
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ited compared to the length of hospital admission (2-week average
duration). Internal review board (IRB) approval was obtained from the
Center for Protection of Human Subjects at Dartmouth College (CPHS
number 21473), and patients provided written informed consent.
Bacterial strains and growth conditions. For the preparation of
genomic DNA (gDNA) from bacterial colonies, we grew Streptococcus
strains aerobically at 37°C, 5% CO2 overnight; Fusobacterium nucleatum,
Prevotella intermedia, and Gemella sp. at 37°C for 48 h anaerobically on
tryptic soy agar (TSA)-5% blood agar plates (Northeast Laboratory Ser-
vices); and Pseudomonas aeruginosa in LB broth at 37°C overnight.
gDNA isolation and patient sputum sample preparation. We em-
ployed a modification of the Gentra PureGene Yeast/Bact. kit to isolate
gDNA. We passed patient sputum samples resuspended and diluted
2-fold to 5-fold in Tris-EDTA (TE)– 0.08% dithiothreitol (DTT) succes-
sively through syringes with 16-, 20-, and 23-gauge needles until homog-
enous. Following treatment for 30 min at 37°C with 3 mg/ml of lysozyme
(final concentration), we incubated the samples in cell lysis buffer
(Gentra) for 15 min at 80°C. The remainder of gDNA isolation fol-
lowed the manufacturer’s protocol. This isolated gDNA was used for deep
sequencing, quantitative real-time PCR (qPCR) studies, and human oral
microbe identification microarray (HOMIM) analysis. gDNA for qPCR
controls was also prepared using the Gentra Puregene Yeast/Bact. kit,
according to the manufacturer’s instructions for Gram-positive or Gram-
negative species, as appropriate.
Deep-sequencing analysis. For pyrotag analyses of the V4V6 rRNA
hypervariable regions in patient sputum gDNA samples, we prepared am-
plicon libraries using fused primers that contained either the A or B 454
Titanium adapter (Roche Diagnostics), a unique 5-nucleotide (nt) mul-
tiplex identifier (MID) for each gDNA sample, and either the conserved
16S rRNA 518F oligonucleotide 5= CCAGCAGCYGCGGTAAN or 1064R,
5= CGACRRCCATGCANCACCT (Escherichia coli 16S rRNA positions).
All MIDs differ by at least two bases and contain no homopolymers. A
master mix contained 1 Platinum HiFi Taq polymerase buffer, 1.6 units
Platinum HiFi polymerase (Life Technologies, Carlsbad CA), 3.7 mM
MgSO4, 200 M deoxynucleoside triphosphates (dNTPs) (PurePeak po-
lymerization mix; ThermoFisher, East Providence RI), and 5 to 20 ng of
gDNA brought to a final volume of 100 l. To mitigate influence of early
PCR errors, we routinely divided the samples into three replicate reactions
and prepared a no-template negative control for each MID. PCR cycling
conditions included initial denaturation at 94°C for 3 min; 30 cycles of
94°C for 30 s, 60°C for 45 s, and 72°C for 1 min; and a final extension at
72°C for 2 min. Replicate samples were pooled to contain equal amounts
of amplicon libraries, based on PicoGreen quantification. After pooling
the three replicates and evaluating the quality of the PCR amplicons and
negative control on a LabChip GX (Caliper, Hopkinton MA), we used a
0.75 volume of Ampure beads (Beckman Coulter, Brea, CA) to remove
products under 300 bp. Subsequent to pooling as many as 40 amplicons
with unique MIDs, we prepared emulsified PCRs and enrichments ac-
cording to the Roche Titanium amplicon sequencing protocols (Lib-A
emPCR reagents, XLR sequencing reagents, two-region PicoTitre plate)
to generate 10,000 to 20,000 pyrotags per library.
Bioinformatics processing. A custom bioinformatic pipeline at the
Marine Biological Laboratory performed quality filtering to remove low-
quality (average quality scores less than 30) reads and sequences lacking
exact primer matches or containing ambiguous bases (Ns). The algorithm
UChime(7),combiningboththedenovoandreferencedatabase(Chimera-
Slayer GOLD) modes, removed chimeric reads. The algorithm GAST as-
signed taxonomy to each unique read (14), and UCLUST (6) identified
operational taxonomic units (OTUs) with 97% sequence identity. The
website Visualization and Analysis of Microbial Population Structures
(http://vamps.mbl.edu) provides access to individual reads, taxon assign-
ments, and descriptions of individual clusters.
qPCR primer set validation. Table 1 specifies the qPCR primer sets,
including the universal primer set originally described by Maeda et al. (16)
and evaluated by Horz et al. (13) for broad-range amplification of bacte-
rial species. All primer sets were verified for specificity using the BLAST
database. The 15 species that served as controls included Pseudomonas
aeruginosa, Streptococcus anginosus, Streptococcus constellatus, Streptococ-
cus intermedius, Streptococcus mitis, Streptococcus oralis, Streptococcus
parasanguis, Streptococcus pneumoniae, Streptococcus salivarius, Strepto-
coccus sanguinis, Prevotella intermedia, Fusobacterium nucleatum, Gemella
haemolysans, Gemella morbillorum and Gemella sanguinis. Detection of
these 15 species with the universal primer set yielded comparable ampli-
fication, with a detection limit of 103 16S rRNA gene copies. The rplU
For/Rev primer set specifically amplifies Pseudomonas aeruginosa with
1.0% nonspecific amplification of all non-Pseudomonas aeruginosa con-
trol species specified above. For these specificity assays, we assigned 100%
amplification for each control species based on total quantification using
the universal primer set and then calculated nonspecific amplification by
the rplU For/Rev primer set accordingly. Similarly, the Str1/2 primer set,
specific for streptococci, amplifies all tested streptococcal species with
equivalent sensitivity with the exception of S. intermedius, which was con-
sistently underrepresented by 5-fold in our optimization assays. The
Str1/2 primer set yielded 0.1% nonspecific amplification of nonstrep-
tococcal species, as defined above for P. aeruginosa. The sensitivity of both
rplU For/Rev and Str1/2 was 25 gene copies. Each primer set had an
efficiency of 90% for amplification of the intended species.
Detection of Pseudomonas aeruginosa and Streptococcus by qPCR.
gDNA purified from control strains was quantified by NanoDrop. We
prepared 10-fold dilutions of gDNA, targeting 16S rRNA gene copy num-
bers of 1  106 to 1  102, based on genome size and 16S rRNA gene copy
number for each species. We assumed a copy number of four for species
that lacked complete genome sequences. We detected 16S rRNA genes by
qPCR, using the universal primer set and 2 iQ SYBR Green supermix
(Bio-Rad) and assigned correction factors for each species’ dilution series
based on detection with the universal primer set to account for error in
NanoDrop quantification, copy number estimation, and dilution prepa-
ration. Pseudomonas aeruginosa was assigned a correction factor of 1.0,
and all other species were assigned accordingly. We prepared a control
mix from the individually prepared species dilutions to contain 63% Pseu-
domonas aeruginosa, 24% Streptococcus, 8% Prevotella intermedia, 3% Fu-
sobacterium nucleatum, and 2% Gemella 16S rRNA gene copies (after cor-
rection factor calculations). The Streptococcus fraction contained
equivalent 16S rRNA gene quantities from each of the nine streptococcal
species listed above, and the Gemella fraction contained equal quantities
of the three Gemella species listed above.
We analyzed patient samples and control mixes in replicates of six for
detection with the universal For/Rev, rplU For/Rev, and Str1/2 primer
TABLE 1 Primers used in qPCR studies
Primer Sequence (5=¡3=) Amplification target Target species Reference(s)
Universal For GTGSTGCAYGGYTGTCGTCA 16S rRNA genes All bacteria 13, 16
Universal Rev ACGTCRTCCMCACCTTCCTC 16S rRNA genes All bacteria 13, 16
rplU For GCAGCACAAAGTCACCGAAGG rplU P. aeruginosa This study
rplU Rev CCGTGGGAAACCACTTCAGC rplU P. aeruginosa This study
Str1 GTACAGTTGCTTCAGGACGTATC tuf Streptococcusa 21
Str2 ACGTTCGATTTCATCACGTTG tuf Streptococcusa 21
a Detects the genus Streptococcus.
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sets. A total of 10 ng of total patient gDNA was analyzed in each well, and
the bacterial portion was 0.02 to 0.2 ng, with the remaining DNA derived
primarily from the host. We prepared standard curves for each primer set
based on quantification cycle (Cq) values for detection of the control mix
dilution series and the known quantities of total 16S rRNA genes, Pseu-
domonas aeruginosa 16S rRNA genes, or Streptococcus 16S rRNA genes in
the control mix. We adjusted the standard curves to account for the fact
that rplU For/Rev and Str1/2 detect genes that are present in single copy
number.
We determined the contribution of 16S rRNA genes from Pseudomo-
nas aeruginosa and Streptococcus in the patient samples via comparison of
replicate Cq detection values to the standard curve for each primer set.
The fraction of Pseudomonas aeruginosa or Streptococcus was further cal-
culated as follows: Pseudomonas aeruginosa-specific 16S rRNA gene de-
tection/universal 16S detection or Streptococcus-specific 16S rRNA gene
detection/universal 16S detection, respectively (see Table 1).
HOMIM. We analyzed purified gDNA from patient sputum samples
by using the HOMIM at The Forsyth Institute. A total of 20 to 30 l gDNA
per sample was analyzed, with a target of 20 ng/l bacterial DNA, when
possible. We prepared gDNA samples and analyzed these samples as de-
scribed on the HOMIM website (http://mim.forsyth.org/protocol.html).
This method was initially published and reviewed by Paster et al. (19, 20).
Statistical analysis. We developed heat maps based on Pearson hier-
archical clustering according to two parameters: (i) patient sample and
(ii) prevalence of microbial genera or species. We calculated a P value for
the association of clinical status and microbial community composition
by Fisher’s exact test.
Box and whisker plots were used throughout the study to compare
microbiome data with clinical phenotypes of interest. The bolded middle
line of the box represents a median value, and the upper and lower ranges
of the box represent the 75% and 25% quartiles, respectively. The whis-
kers depict 1.5 the interquartile range. Open circles display data points
that fall outside 1.5 the interquartile range. We calculated P values for all
box-and-whisker plots by the nonparametric Mann-Whitney U test.
Comparison of the fractional representation of individual genera in
inpatient or outpatient samples was displayed in a transition plot. We
calculated significant differences between means by t test using Benja-
mini-Hochberg-corrected P values.
We plotted 454 pyrosequencing results and median fraction values for
qPCR detection of Pseudomonas and Streptococcus to show relationships
between these data and calculated Pearson correlation lines and P values,
excluding the indicated outlier points, as described thoroughly in Results.
RESULTS
Characterization of the microbiome of sputum from CF pa-
tients. The patient cohort studied here includes 39 CF patients
recruited as part of a previously reported cross-sectional study (8).
At the time of sputum collection, 25 participants were clinically
stable (outpatient status) and 14 participants were in a state of
clinical worsening (inpatient status). The average age of the out-
patient population was 27.5 years (range, 19 to 52 years) and was
27.5 years (range, 22 to 45 years) for the inpatient group. The
outpatient group consisted of 44% females and, similarly, the in-
patient group consisted of 43% females. Relatively low FEV1 was
characteristic of patients during exacerbation, which correlated
with inpatient status. The inpatient cohort had a median FEV1 of
27% predicted, while the outpatient population had a median
FEV1 of 56% predicted. Additionally, both the inpatient and out-
patient groups included participants who were either on or off
maintenance tobramycin treatment at the time of sample collec-
tion. Further clinical description and analysis of this patient co-
hort was previously reported (8).
Genomic DNA (gDNA) was prepared from spontaneously
produced patient sputum samples and the 16S rRNA gene profiles
characterized by 454 pyrosequencing of amplicon libraries, as re-
ported by Sogin et al. (29) and Huse et al. (14), for 35 of the 39
patients (22 outpatients and 13 inpatients). Genus assignments
were resolved for 99% of the total deep-sequencing reads.
A total of 138 genera were assigned for the 35 patient samples.
A complete summary of read assignments for each patient is pro-
vided in Tables S1 and S2 in the supplemental material. The most
dominant genera in this sample set included Pseudomonas, Strep-
tococcus, Fusobacterium, and Prevotella, followed by Rothia,
Stenotrophomonas, Staphylococcus, Haemophilus, Gemella, and
Neisseria (Fig. 1A). These 10 genera accounted for 93% of the
reads detected from the patient samples. While not all 10 of the top
genera were present in every patient, each genus accounted for at
least 1% of the total reads for the patient population as a whole.
The presence of these genera in CF patient lungs agrees with the
findings reported previously (3, 26, 32).
Figure 1B shows patient samples clustered according to deep-
sequencing profiles of the overall most abundant four genera,
which accounted for 86% of the total reads. These top-four genera
are also highly prevalent in the patient population, meaning that
they are present in most patients. Remaining genera are highly
abundant (when present), highly prevalent (but not highly abun-
dant), or neither highly abundant nor prevalent (see Fig. S1 in the
supplemental material). While some low-prevalence and/or low-
abundance organisms may have significant biological impact, for
initial profiling of this patient cohort, only the top-four most
abundant and prevalent organisms were analyzed. Focusing on
only the top-four genera of the data set, we have identified four
exploratory community profiles in which the patient samples
cluster: (i) high Pseudomonas, low Streptococcus; (ii) medium
Pseudomonas, medium Streptococcus; (iii) low Pseudomonas, high
Streptococcus; and (iv) low Pseudomonas, low Streptococcus, but
high other (predominantly Fusobacterium or Prevotella).
Overall, the association between clinical status and these four
exploratory clusters is greater than one would expect by chance
(P  0.01, Fisher’s exact test), indicating that most clusters are
significantly enriched in samples derived from uniquely inpatients
or outpatients. However, predominance of Pseudomonas in a pa-
tient sample is not predictive of patient status (as profile 1 is com-
posed of both inpatient samples and outpatient samples). Figure
1B also displays that Pseudomonas constitutes the single predom-
inant genus in only about half of the patient samples from this
cohort, whereas the remaining samples are predominated by a
combination of Pseudomonas and Streptococcus or other prevalent
genera.
Increased diversity correlates with outpatient status. Our
comparisons of microbial profiles with patient clinical informa-
tion (8) revealed several significant correlations. (i) Outpatient
samples had significantly higher diversity than inpatient samples
(Fig. 2A). Differences in the deep-sequencing effort for each group
do not explain this correlation since the outpatient and inpatient
samples had a comparable number of reads (see Fig. S2 in the
supplemental material). (ii) The state of being on or off mainte-
nance treatment with tobramycin at the time of sputum collection
(irrespective of clinical status) did not significantly affect micro-
bial diversity (Fig. 2B), although we observed a trend toward
higher diversity for those patients off tobramycin. Similarly, Zhao
and colleagues recently reported that maintenance antibiotic ad-
ministration had a minimal impact on the microbial diversity in
sputum samples from a longitudinal study of six patients. How-
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ever, episodic antibiotic treatment of pulmonary exacerbations
significantly decreased microbial diversity during their longitudi-
nal study (32). (iii) Maintenance treatment with tobramycin did
not correlate with the fraction of Pseudomonas or Streptococcus in
the sputum samples (see Fig. S3 in the supplemental material).
(iv) Patient age did not correlate with diversity for any compari-
sons (data not shown). This finding is also consistent with the
results described in Zhao et al., where no significant correlation
between microbial community diversity and age was observed
(32). (v) The fraction of Pseudomonas did not correlate with any
clinical parameters collected for this patient cohort. Of particular
note, no significant correlation was observed between the fraction
of Pseudomonas and inpatient or outpatient status (Fig. 3A).
Streptococcus abundance correlates with clinically stable
lung disease. Based on the finding that outpatients have increased
bacterial diversity in their sputum, we explored correlations be-
tween patient status (i.e., inpatients versus outpatients) and prev-
alence of individual genera. The deep-sequencing data showed a
significantly higher Streptococcus fraction in outpatients than in
inpatients (Fig. 3B). The analysis shown in Fig. 1B confirms this
observation by showing that inpatient samples clustered to the
low proportion of streptococcus profiles, whereas more than 50%
of the outpatients had a midlevel to high proportion of strepto-
coccus. This correlation between increased Streptococcus fraction
and patient stability is independent of the Pseudomonas fraction
(Fig. 3A). While there is a trend toward increased Pseudomonas
fraction in inpatients compared to that in outpatients, this differ-
ence is not statistically significant. Similarly, no significant corre-
lation with patient status was detected for Fusobacterium or Pre-
votella (data not shown).
FIG 1 Characterization of the polymicrobial communities of sputum samples from cystic fibrosis inpatients and outpatients. (A) Fraction of 454 pyrosequenc-
ing reads assigned to each of the top-10 genera detected in the patient sample set as a whole is shown for sputum samples analyzed from inpatients (INPT; n 
13) and outpatients (OUTPT; n  22) from a cross-sectional study. The legend indicates the color assigned to each indicated genus. (B) Heat map of patient
samples based on Pearson hierarchical clustering of relative bacterial abundance (by deep sequencing) for the most prevalent four genera, which account for
86% of the total pyrosequencing reads. Patients can be described as one of four profiles: (i) high Pseudomonas, low Streptococcus; (ii) medium Pseudomonas,
medium Streptococcus; (iii) low Pseudomonas, high Streptococcus; (iv) low Pseudomonas, low Streptococcus, but high other (primarily Fusobacterium or Prevotella).
The group number is indicated in the bar at the bottom of the panel, and the inset key indicates the color associated with the fraction of reads for each patient and
genera assigned.
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Less predominant genera may also have a significant impact on
microbial community dynamics and clinical outcome. Fractional
representation of all genera assigned in this data set was compared
for outpatients and inpatients (Fig. 3C). Most strikingly, the frac-
tional representation of the genus Gemella (which accounts for
2% of the total reads for this sample set) is greater than 30-fold
higher in outpatients than in inpatients. Interestingly, Haemophi-
lus (similarly, 2% of the total reads) is also enriched in outpa-
tient samples compared to in inpatient samples. The biological
significance of the increased fractional representation of these or-
ganisms in the outpatient samples compared to in the inpatient
samples is not understood at this time.
qPCR analysis confirms the genus population profiling de-
termined by 454 pyrosequencing. Deep-sequencing analysis of
polymicrobial samples by 454 pyrosequencing has gained wide-
spread acceptance as a method for profiling clinical specimens.
However, few reports independently verify the results of deep-
sequencing data. To address this issue, we employed a qPCR
method to confirm our deep-sequencing results. For these studies,
we used a combination of species-specific and group-specific
primer sets from previous publications or newly developed prim-
ers (Table 1). We validated all primers for their accurate detection
of and specificity toward control gDNA from representative spe-
cies of the top genera in the patient sputum (see Materials and
Methods for details).
We used Pseudomonas aeruginosa-specific, Streptococcus-spe-
cific, and universal primer sets in qPCR assays of the 19 (out of the
35) patient sputum samples that contained sufficient gDNA for
both pyrosequencing and qPCR analysis. The fraction of Pseu-
domonas aeruginosa and Streptococcus present in each patient sam-
ple is calculated based on comparison to standard curves devel-
oped from a known mixture of bacterial gDNA (see Materials and
Methods for details).
qPCR measurement of the fraction of Pseudomonas aeruginosa
in inpatient and outpatient samples positively correlated with the
fraction of 454 pyrosequencing reads assigned to the Pseudomonas
genus for each sample (Fig. 4A). The Pearson correlation of the
Pseudomonas plot has a value of 0.968. Further, the regression line
has a slope of 1.08, indicating that qPCR yielded marginally higher
values than deep sequencing. qPCR results confirm that Pseu-
domonas aeruginosa accounts for the vast majority of Pseudomo-
nas present in CF patient sputum. Similarly, we observed a direct
correlation between the fraction of Streptococcus species detected
by qPCR and by deep sequencing (Fig. 4B). The deep-sequencing–
qPCR regression line for Streptococcus has a slope of 1.03 and a
Pearson correlation value of 0.941. The residuals are uniformly
distributed for both plots, indicating that the errors are unbiased.
Two outlying samples were detected in our analysis. These
samples display differential measurements by qPCR and deep se-
quencing of Pseudomonas aeruginosa in INPT 12 and Streptococcus
in OUTPT 11. We did not include these samples in the analysis of
FIG 2 Increased diversity correlates with outpatient status and is not im-
pacted by tobramycin treatment. Box-and-whisker plots of the Simpson diver-
sity index based on the complete deep-sequencing profile of each sputum
sample (each read assigned to a single genus). Box parameters, the bold line
represents median diversity, while the upper and lower ranges of the box rep-
resent the 75% and 25% quartiles, respectively; whisker parameters, 1.5 the
interquartile range; open circles, data points that fall outside 1.5 the inter-
quartile range. P values were calculated using the nonparametric Mann-Whit-
ney U test. (A) Inpatient (INPT; n  13) samples compared to outpatient
(OUTPT; n  22) samples. The asterisk indicates P values 0.05. (B) Com-
parison of sputum samples collected from patients off tobramycin antibiotic
treatment (Off Tobi; n  24) compared to on tobramycin (On Tobi; n  11),
irrespective of patient status. No significant difference in diversity was de-
tected.
FIG 3 Increased Streptococcus fraction correlates with clinical patient stability.
Box-and-whisker plots comparing the fraction of 454 pyrosequencing reads
assigned to a single genus for inpatient and outpatient samples. Median frac-
tion Streptococcus or Pseudomonas is represented by the bold middle line of the
box. The extremities of the box represent the 75% and 25% quartiles. The
whiskers of the plot indicate 1.5 the interquartile range. P values were calcu-
lated using the nonparametric Mann-Whitney U test. (A) Comparison of
Pseudomonas fraction; (B) comparison of Streptococcus fraction. The asterisk
indicates P values 0.05. (C) Transition plot comparing the fractional repre-
sentation of taxonomic read assignments in inpatient samples to outpatient
samples, based on 454 pyrosequencing results. Plotted circles correspond to
the log2-fold difference in fractional representation of an individual taxon
between the inpatient cohort and the outpatient cohort. t test comparisons of
relative abundance in inpatient versus outpatient samples for all genera de-
tected in the sample set were performed, and the reported P values are Benja-
mini-Hochberg corrected for multiple hypothesis testing. Key: open circles, no
significant difference in fractional representation, P  0.05; gray circles, sig-
nificantly higher fractional representation in outpatient samples, P  0.05. No
detected genera were significantly enriched in inpatient samples compared to
in outpatient samples after Benjamini-Hochberg correction. Genera are la-
beled in the order they are located on the transition plot (most significantly
different at the bottom). Relative fractional representation in the total sample
set is specified for each labeled genus.
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regression lines. Pseudomonas pyrotags accounted for 98% of the
deep-sequencing reads for INPT 12, while qPCR measured only
13% Pseudomonas aeruginosa in that same sample using the rplU
primer set. For this sample, a second Pseudomonas aeruginosa-
specific primer set, targeted to an alternative gene, oprD, also
underreported Pseudomonas aeruginosa compared to 454 pyrose-
quencing (not shown). These results may indicate that a non-
aeruginosa species of the genus Pseudomonas predominates in this
sample.
Additionally, a discrepancy in the measurement of the fraction
of the Streptococcus genus was seen between the two methods for
OUTPT 11. In this sample, the qPCR method detected 19% Strep-
tococcus, while 454 pyrosequencing detected 58% Streptococcus.
While we do not fully understand the reason for this discrepancy,
we note that the GAST algorithm used here resolved the Strepto-
coccus reads for this patient sample to the species level and they
were assigned to Streptococcus pneumoniae (not shown). Therefore,
this sample was analyzed using a Streptococcus pneumoniae-spe-
cific primer set targeted to psaA. Similar to the Streptococcus genus
analysis, qPCR measured 13% Streptococcus pneumoniae in
OUTPT 11, an underrepresentation compared to the deep-se-
quencing results. Technical or biological factors related to
OUTPT 11 are not germane to the central thesis of this report and
will be explored at a later date.
Overall, the qPCR assay presented and validated here provides
an alternate, high-throughput method for analyzing complex,
polymicrobial patient samples. This assay can be used to broadly
characterize the sputum microbiome, as well as verify trends de-
termined in deep-sequencing experiments.
Oral streptococci and the SMG species are the predominant
streptococci detected in the patient sputum samples. The corre-
lation observed between the fractional representation of Strepto-
coccus and clinically stable disease (i.e., outpatients) prompted us
to further characterize the streptococcal species in the patient
samples. A selection of 13 samples (8 outpatients and 5 inpatients
for which sufficient sputum-derived gDNA was available) was an-
alyzed on the HOMIM, which contains probes for the detection of
300 oral species, including the majority of Streptococcus species
previously identified in CF patient sputum samples (17). Each
analyzed sputum gDNA sample is scored based on relative inten-
sity of hybridization for each probe on the microarray and is as-
signed a semiquantitative value of 0 to 5, where 0 is no hybridiza-
tion above background and 5 is intense hybridization to probe.
Table S3 in the supplemental material displays a complete list of
hybridization intensity score assignments to all probes for the 13
samples analyzed by HOMIM.
As a control, HOMIM analysis confirmed the presence of
Pseudomonas aeruginosa in the 13 samples analyzed. Further,
the overall bacterial community profiles determined by
HOMIM correlated with the pyrosequencing results (see Table
S1 in the supplemental material). Ahn et al. previously re-
ported the correlation of these two methods (1).
The HOMIM results for the 13 selected samples showed that
the patient samples hybridized most strongly to probes targeted to
Streptococcus salivarius, Streptococcus parasanguis, and SMG spe-
cies (Fig. 5). As can be seen from the heat map derived from the
HOMIM data, the outpatient samples cluster separately from the
inpatient cohort. The majority of strong hybridization to Strepto-
coccus sp. probes was detected in the outpatient samples, with
minimal hybridization occurring with the inpatient cluster. This
finding is consistent with the higher fraction of Streptococcus de-
tected in the outpatient group than the inpatients, as validated via
454 pyrosequencing (Fig. 3B) and qPCR (Fig. 4B).
DISCUSSION
Microbiome analysis of this cohort of CF patients showed a cor-
relation between inpatient status and decreased sputum bacterial
diversity. Inpatient status for this cohort was previously shown to
correlate with increased prevalence of cystic fibrosis-related dia-
betes and low FEV1, low serum iron, and high sputum iron levels,
a phenotype of more severe disease (8). However, the impact of
individual species or interspecies interactions for each of these
phenotypes remained unexplored. Importantly, clinical observa-
tions may suggest testable hypotheses about how underlying poly-
microbial community composition, diversity, and relative abun-
dance may alter the disease process in CF.
The current dogma in the field of CF dictates that Pseudomonas
aeruginosa is the predominant organism in the majority of CF
patients. Culture-independent methods of analyzing CF patient
lower respiratory samples are slowly remodeling our understand-
ing of the complexity of these microbial communities. The mo-
lecular profiling of 35 sputum samples reported here shows that
the current dogma held true in about half the patient samples (Fig.
1B). For the remaining half, each patient sample was dominated
by a non-Pseudomonas genus or a combination of Pseudomonas
and Streptococcus. Further, communities dominated by a non-
Pseudomonas genus were identified in both outpatients and inpa-
tients. The prevalence of these alternative genera and their poten-
tial role in acute exacerbation is an essential factor that should be
considered in future studies.
While 454 pyrosequencing, Illumina sequencing, and Ion Tor-
rent technologies have gained popularity for microbiome analysis
of clinical samples, this investigation provides independent veri-
fication of deep-sequencing findings. To this end, the qPCR assays
of the sputum DNA samples largely confirmed the Pseudomonas
and Streptococcus profiles as determined by 454 pyrosequencing.
FIG 4 qPCR analysis independently verifies 454 pyrosequencing detection of
the most prevalent bacteria in cystic fibrosis patient sputum samples. (A) The
fraction of Pseudomonas aeruginosa determined by qPCR (rplU detection/uni-
versal detection) correlates to the fraction of deep-sequencing reads assigned
to the Pseudomonas genus. Pearson correlation  0.968. (B) The fraction of
Streptococcus determined by qPCR (tuf detection/universal detection) corre-
lates to the fraction of deep-sequencing reads assigned to the Streptococcus
genus. Pearson correlation  0.941. All samples were analyzed in replicates of
six for each primer set, with the exception of OUTPT 11 (n  3). Median
fraction values for each sample are plotted for qPCR detection and were used
for the correlation analysis. Pearson correlation lines were calculated, exclud-
ing the outlier points. Legend: open circle, outpatient (OUTPT); black closed
circle, inpatient (INPT); gray closed circle, outlier.
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Measurement of the fractional representation of these two pre-
dominant genera correlated for the two methods in 18 out of 19
samples. However, a single outlier in the detection of Pseudomo-
nas or Streptococcus occurred in two distinct samples, described in
detail in Results (see Fig. 4). For the Pseudomonas outlier (INPT
12), our data are consistent with the conclusion that a non-aerugi-
nosa strain may predominate in this patient. Although we do not
understand the discrepancy in the fraction of Streptococcus mea-
sured by qPCR and 454 pyrosequencing for this single outlier
(OUTPT 11), it may be due to PCR conditions or primer specific-
ity or possibly represent an interesting aspect of the microbiology
of this patient warranting further investigation. While each indi-
vidual method largely results in consistent profiling of the domi-
nant genera of CF patient sputum, only through the combination
of the qPCR and deep-sequencing methods were we able to iden-
tify these unique outlier samples.
We further profiled the species of streptococci present in our
patient samples using the HOMIM. In this analysis, species tar-
FIG 5 Oral streptococci and streptococcal species are prevalent in CF sputum samples. Shown is the assignment of relative abundance (score of 0 to 5) for each
sample based on intensity of hybridization to each Streptococcus-specific 16S rRNA gene probe. Probes are species specific, group specific (hybridize 2 to 3 oral
taxon), or cluster specific (hybridize multiple streptococcal oral taxon). Pearson hierarchical clustering was performed based on hybridization intensity in two
dimensions: (i) probe and (ii) patient sample.
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geted by probes for oral cavity-associated streptococci and the
SMG species were hybridized most strongly. The predominance of
S. salivarius and S. parasanguis in our outpatient samples is con-
sistent with previous reports (17). The prevalence of SMG species
in our CF patients is also consistent with previous findings by
Sibley et al. (28). However, in their patient cohort, Sibley et al.
showed that the SMG species were associated with acute exacer-
bations, while in our cross-sectional patient cohort, SMG species
were most abundant in the clinically stable patients. We suggest
that modest levels of S. salivarius, S. parasanguis, and SMG species
may increase the diversity of the CF lung and contribute to patient
health, while excessive levels, particularly of SMG species, may
lead to increased pathogenicity and clinical decline.
The samples analyzed here are complex due to a multitude of
clinical treatment, host, and microbial factors that should be
considered when interpreting the results of this sample set.
Intravenous antibiotics may have initial impacts on the micro-
bial community of exacerbating patients, including altering
overall diversity, as early as within the first 24 h of hospital admit-
tance, even though no consistent clinical improvement was ob-
served this early during admittance. Of note, inpatients were
treated with combinatorial antibiotic therapy that does not target
any single microbial population. Additionally, gDNA of killed
bacterial cells during early admittance may persist in the sputum.
However, we are unaware of any studies specifying the persistence
and rates of decay of gDNA in patient sputum for organisms prev-
alent in CF.
Furthermore, due to the passage of sputum through the oral
cavity prior to sample collection, the effect of potential salivary
contamination should be considered. There is strong evidence
that the Streptococcus sp. and other oral cavity-associated species
in sputum samples derive from the lung rather than from contam-
ination with saliva. Rogers et al. showed that oral mouthwash
samples compared to sputum samples from a single patient
contain distinct polymicrobial communities (25). Addition-
ally, Harris et al. analyzed bronchoalveolar lavage (BAL) fluid
from children with cystic fibrosis and detected various oral
cavity-associated organisms, including Streptococcus sp., Pre-
votella sp., Fusobacterium sp., and others. Collection of BAL fluid
samples bypasses the oral cavity, verifying prevalence of these or-
ganisms in patient lungs (12). Further, our work presented here
shows that the 454 pyrosequencing, qPCR, and HOMIM all dis-
play the same significant difference in the relative abundance of
Streptococcus in outpatient samples compared to that in inpatient
samples. Given that both inpatients and outpatients provided spu-
tum samples by spontaneous expectoration, any potential con-
tamination of samples with saliva would equally affect both sam-
ples sets. While variability in the volume of expectorated sputum
samples existed between patients, we did not detect any correla-
tion between the volume of sputum expectoration and fractional
representation of Streptococcus by deep sequencing (not shown).
Therefore, we conclude that the Streptococcus in outpatient spu-
tum samples specifically reflects their presence in the CF lung.
It is formally possible that less prevalent organisms, such as
Gemella or Haemophilus, drive microbial community dynamics in
CF patient lungs. Here, we focus on Streptococcus due to its signif-
icant correlation with outpatient clinical status, its high abun-
dance, and its high prevalence in this patient cohort. Overall, the
increased fractional representation of numerous low-abundance
genera in outpatient samples may increase the diversity of the
corresponding lung communities, perhaps promoting clinical sta-
bility.
Further analyses of the community structure and interspecies
interactions in the lungs of CF patients may reveal markers for the
development of acute exacerbation as well as build our under-
standing of healthy microbial communities that promote patient
stability. Furthermore, the microbial community associations de-
tected from the sputum samples of this patient cohort will be used
to guide our future in vitro studies exploring the underlying mech-
anisms and microbial interactions of the CF lung environment,
which will facilitate personalized patient treatment and the devel-
opment of novel therapeutics.
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